Skip to main content

Advertisement

Log in

Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Adoptive immunotherapy with antitumor effector cells is an attractive therapeutic approach in metastatic renal cell carcinoma (RCC). The aim of the work was to enhance in vitro activation of lymphocytes with optimal cytotoxic activity against tumor cells. We evaluated a procedure based on the use of dendritic cells (DCs) loaded with irradiated tumor cells (DC-Tu) to stimulate lymphocytes. Experimental conditions were established with cells from healthy donors and melanoma cell lines. Procedures were then applied to cells from RCC patients. A total of 30 tumor biopsies, 14 proximal lymph nodes, and 17 peripheral blood samples from 30 patients were used. When lymphocytes were stimulated in vitro with DC-Tu, they responded to tumor cells with an increased cytolytic activity for all the assays with donor cells (n=18). For RCC patients, DC-Tu stimulation improved the final cytotoxic activity in only half of the assays (16/31). When significantly enhanced (>10%, n=8), responder cells resulted in a final 43% cytotoxicity against autologous RCC cells. Mechanism of lysis was at least in part class I mediated. Effector cells have no lytic activity against normal renal cells. Percentage of cells with regulatory T-cell phenotype was not found to be enhanced in the DC-Tu stimulated lymphocytes. Individual differences were observed in the characteristics of DCs generated from RCC patients in contrast to that observed in donors and could explain why lymphocyte stimulation was not improved by DC-Tu in half of the RCC assays. T-cell spreading was suitable for a therapeutic use (>109 cells) irrespective of the procedure (with or without DC-Tu stimulation) or the tissular origin of lymphocytes from patients. Data show that precursors of selective antitumor effector cells are present in patients with RCC and can be amplified in vitro either with or without DC-Tu stimulation. One of these populations could be chosen for an adoptive transfer immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Almand B, Clark JI et al (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689

    CAS  PubMed  Google Scholar 

  2. Belldegrun A., W. Pierce et al (1993) Interferon-α primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-α as therapy for metastatic renal cell carcinoma. J Urol 150:1384–1390

    CAS  PubMed  Google Scholar 

  3. Bernhard H, Karbach J et al (1994) Cellular immune response to human rena-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer 59:837–842

    CAS  PubMed  Google Scholar 

  4. Boisteau O, Gautier F et al (1997) Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis 1997:403–412

    Google Scholar 

  5. Bouet-Toussaint F, Genetet N et al (2000) Interleukin 2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytokin Network 11(2):217–224

    CAS  Google Scholar 

  6. Caignard A, Guillard M et al (1996) In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int J Cancer 66:564–570

    Article  CAS  PubMed  Google Scholar 

  7. Delneste Y, Magistrelli G et al (2002) Involvement of LOX-1 in dendritic cell mediated antigen cross-presentation. Immunity 17(3):353

    CAS  PubMed  Google Scholar 

  8. Dudley M, Wunderlich J et al (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor-antigen specific T lymphocytes in patients with metastatic melanoma. J Immunother 25(3):243–51

    Article  CAS  PubMed  Google Scholar 

  9. Figlin R, Pierce W et al (1997) Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8+ selected tumor infiltrating lymphocytes from primary tumor. J Urol 158:740–745

    CAS  PubMed  Google Scholar 

  10. Figlin RA, Thompson JA et al (1999) Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17:2521–2529

    CAS  PubMed  Google Scholar 

  11. Finke JH, Rayman P et al (1992) Characterisation of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 11:1–11

    CAS  PubMed  Google Scholar 

  12. Fuhrman SA, Lasky LC et al (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663

    CAS  PubMed  Google Scholar 

  13. Goey SH, Verweij J et al (1996) Immunotherapy of metastatic renal cell cancer. Annals of Oncology 7:887–900

    CAS  PubMed  Google Scholar 

  14. Groh V, Rhinehart R et al (2001) Costimulation of CD8αβTcells by NKG2D via engagement by MIC induced on virus-infected cells. Nature Immunology 2:255–260

    Article  CAS  PubMed  Google Scholar 

  15. Guinan P, Sobin LH et al (1997) TNM staging of renal cell carcinoma: workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80(5): 992–993

    Article  CAS  PubMed  Google Scholar 

  16. Hänninen EL, Kirchner H et al (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155:19–25

    PubMed  Google Scholar 

  17. Hayakawa M, Hatano T et al (1994) Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2. Urol Int 53:117–124

    CAS  PubMed  Google Scholar 

  18. Hoffmann T, Meidenbauer N et al (2000) Generation of tumor-specific T-lymphocytes by cross-priming human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60(13):3542–3549

    CAS  PubMed  Google Scholar 

  19. Jonuleit H, Schmitt E et al (2001) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends in immunology 22(7):394–400

    Article  CAS  PubMed  Google Scholar 

  20. Jotereau F, Pandolfino MC et al (1991) High fold expansion of human cytotoxic t-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10:405–411

    CAS  PubMed  Google Scholar 

  21. Kugler A, Stuhler G et al (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6(3):332–336

    CAS  PubMed  Google Scholar 

  22. Liau LM, Black KL et al (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115–1124

    CAS  PubMed  Google Scholar 

  23. Mathiot C, Thiounn N et al (1995) Non-cytotoxic CD4 Tumour-infiltrating lymphocytes induce responses in patients with metastatic renal cell carcinoma previously treated with interleukin-2. Eur J Cancer 31A(9):1552–1553

    PubMed  Google Scholar 

  24. Menetrier-Caux C, Thomachot M et al (2001) IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res 61(7):3096–3104

    CAS  PubMed  Google Scholar 

  25. Motzer RJ, Mazumdar M et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8):2530–2540

    CAS  PubMed  Google Scholar 

  26. Mulders P, Tso C-L et al (1999) Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 5:445–454

    CAS  PubMed  Google Scholar 

  27. Negrier S, Escudier B et al (1998) Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272–1278

    Article  CAS  PubMed  Google Scholar 

  28. Nestlé FO, Alijagic S et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328–332

    CAS  PubMed  Google Scholar 

  29. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179(4):1109–1118

    CAS  PubMed  Google Scholar 

  30. Thurnher M, Radamyr C et al (1996) Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68:1–7

    CAS  PubMed  Google Scholar 

  31. Weng NP, Levine BL et al (1995) Human naive and memory T lymphocytes differ in telomeric lenght and replicative potential. Proc Natl Acad Sci USA 92:11091–11094

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Marc Grégoire (INSERM U419, Nantes) for helpful discussion of the data.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Véronique Catros-Quemener.

Additional information

This work was supported by grants from the Comité Grand Ouest de La Ligue Contre le Cancer and from the Faculté de Médecine de Rennes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bouet-Toussaint, F., Patard, JJ., Gervais, A. et al. Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use. Cancer Immunol Immunother 52, 699–707 (2003). https://doi.org/10.1007/s00262-003-0412-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-003-0412-9

Keywords

Navigation